Additional mechanisms may be needed to detect misbehaving and malicious traffic sources.
To eliminate malaria in coming decades, new ultra-sensitive diagnostics will be needed to detect both drug resistance and latent reservoirs in asymptomatic individuals.
After sample size calculations indicated that 147 patients would be needed to detect a 25% difference between drug and control, 153 patients with MPS were recruited and randomized to receive either a diclofenac sodium patch or control (menthol) patch.
Power analyses indicated that a minimum of 38 samples would be needed to detect this correlation with a power of 90% and an α of 0.05.
Optimal gain settings, recognition of posterior acoustic enhancement, and identification of the to-and-fro motion of pus with probe pressure may be needed to detect such abscesses.
A repeat sample size calculation suggested that an estimated 48 patients would be needed to detect a correlation of 0.45 (α = 0.05, power = 0.9).
For instance, Roberts et al. calculated that a sample size of 560 patients in each dosing protocol would be needed to detect difference in bacteriological outcomes [75].
Better models may be needed to detect subtle regulation defects.
However, long periods of observation may be needed to detect tumors.
Complementary genetic, biochemical or protein-protein interaction studies will be needed to detect such genes/gene products [74], [75].
Post-hoc power analyses revealed that, with alpha of 0.05 and beta of 0.80, a minimum of 220 participants per group would be needed to detect a significant effect.
